Activator protein-1 in liver pathology: from precancerous diseases to hepatocellular carcinoma

被引：0

作者：

Villarruel-Melquiades, Fernanda ^{[1
]}

Aguirre-Maldonado, Isaac ^{[1
,2
]}

Herrera-Lopez, Ema Elvira ^{[1
,2
]}

Mendoza-Garrido, Maria Eugenia ^{[3
]}

Perez-Carreor, Julio Isael ^{[2
]}

Banuelos, Cecilia ^{[4
]}

Camacho, Javier ^{[1
]}

机构：

[1] Inst Politecn Nacl, Ctr Invest & Estudios Avanzados, Dept Farmacol, Ave IPN 2508, Ciudad De Mexico 07360, Mexico

[2] Inst Nacl Med Genom INMEGEN, Ciudad De Mexico 14610, Mexico

[3] Inst Politecn Nacl, Ctr Invest & Estudios Avanzados, Dept Fisiol Biofis & Neurociencias, Ciudad De Mexico 07360, Mexico

[4] Inst Politecn Nacl, Programa Transdisciplinario Desarrollo Cient & Tec, Ctr Invest & Estudios Avanzados, Dept Invest & Estudios Multidisciplinarios, Ciudad De Mexico 07360, Mexico

来源：

HEPATOMA RESEARCH | 2024年 / 10卷

关键词：

Activator protein-1; liver pathology; hepatocellular carcinoma; liver carcinogenesis; transcription factors; VIRUS X-PROTEIN; MATRIX METALLOPROTEINASE-1 EXPRESSION; NF-KAPPA-B; C-JUN; TRANSCRIPTION FACTOR; HEPATITIS-B; CYCLIN D1; MATRIX-METALLOPROTEINASE-9; GENE; CELL-PROLIFERATION; SIGNALING PATHWAY;

D O I：

10.20517/2394-5079.2024.95

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Activator protein 1 (AP-1) is a family of transcription factors composed of Jun, Fos, activating transcription factor (ATF), and musculoaponeurotic fibrosarcoma (MAF) homodimers and heterodimers that regulate diverse cellular processes such as proliferation, apoptosis, differentiation, survival, and migration. Accordingly, AP-1 plays an essential role in several diseases including cancer. During liver cancer development, AP-1 abnormal activation has been implicated from cancer initiation to cancer progression. This review aims to provide a current integrative understanding of the role of AP-1 in liver carcinogenesis and suggests potential settings for its clinical use in diagnosis and treatment. Novel AP-1-based therapeutic approaches deserve further investigation and clinical application for the benefit of liver cancer patients.

引用

页数：19

共 50 条

[41] Effectiveness of transarterial chemoembolization in combination with lenvatinib and programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma
Chisthi, Meer M.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 16 (07)
[42] Expression of activator protein-1 (AP-1) family members in breast cancer
Kharman-Biz, Amirhossein
Gao, Hui
Ghiasvand, Reza
Zhao, Chunyan
Zendehdel, Kazem
Dahlman-Wright, Karin
BMC CANCER, 2013, 13
[43] Activator Protein-1 Decoy Oligodeoxynucleotide Transfection Is Beneficial in Reducing Organ Injury and Mortality in Septic Mice
Imaizumi, Takahiro
Matsuda, Naoyuki
Tomita, Kengo
Palikhe, Sailesh
Ohashi, Wakana
Hattori, Kohshi
Hattori, Yuichi
CRITICAL CARE MEDICINE, 2018, 46 (05) : E435 - E442
[44] Activator protein-1 transactivation of the major immediate early locus is a determinant of cytomegalovirus reactivation from latency
Krishna, Benjamin A.
Wass, Amanda B.
O'Connor, Christine M.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2020, 117 (34) : 20860 - 20867
[45] Linking fatty liver diseases to hepatocellular carcinoma by hepatic stellate cells
Chen, Liang'en
Ye, Xiangshi
Yang, Lixian
Zhao, Jiangsha
You, Jia
Feng, Yuxiong
JOURNAL OF THE NATIONAL CANCER CENTER, 2024, 4 (01): : 25 - 35
[46] Current Trends and Characteristics of Hepatocellular Carcinoma in Patients with Autoimmune Liver Diseases
Rigopoulou, Eirini I.
Dalekos, George N.
CANCERS, 2021, 13 (05) : 1 - 20
[47] Efficacy of transarterial chemoembolization prior to liver transplantation for hepatocellular carcinoma as found in pathology
Sotiropoulos, GC
Malagó, M
Molmenti, E
Paul, A
Nadalin, S
Brokalaki, EI
Verhagen, R
Dirsch, O
Gerken, G
Lang, H
Broelsch, CE
HEPATO-GASTROENTEROLOGY, 2005, 52 (62) : 329 - 332
[48] Expression of deleted in liver cancer 1 and plasminogen activator inhibitor 1 protein in ovarian carcinoma and their clinical significance
Ren, Fang
Shi, Huirong
Zhang, Gong
Zhang, Ruitao
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2013, 32
[49] SERUM FERRITIN IN HEPATOCELLULAR-CARCINOMA AND BENIGN LIVER-DISEASES
LOPEZ, JB
THAMBYRAJAH, V
BALASEGARAM, M
SATGUNASINGAM, N
DIAGNOSTIC ONCOLOGY, 1994, 4 (04): : 143 - 147
[50] Absence of association between pretransplant serum soluble programmed death protein-1 level and prognosis following living donor liver transplantation in patients with hepatocellular carcinoma
Na, Byeong-Gon
Kim, Yun Kyu
Hwang, Shin
Lee, Kyung Jin
Park, Gil-Chun
Ahn, Chul-Soo
Kim, Ki-Hun
Moon, Deok-Bog
Ha, Tae-Yong
Song, Gi-Won
Jung, Dong-Hwan
Yang, Hunji
Yoon, Young-In
Tak, Eunyoung
Park, Yo-Han
Lee, Sung-Gyu
MEDICINE, 2021, 100 (17) : E25640

← 1 2 3 4 5 →